Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H23ClN4O2.C4H6O4 |
| Molecular Weight | 444.91 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CCC(O)=O.CCN1CC(CN1CC)NC(=O)C2=CC(Cl)=C(N)C=C2OC
InChI
InChIKey=HLDCRAZAHFKARV-UHFFFAOYSA-N
InChI=1S/C15H23ClN4O2.C4H6O4/c1-4-19-8-10(9-20(19)5-2)18-15(21)11-6-12(16)13(17)7-14(11)22-3;5-3(6)1-2-4(7)8/h6-7,10H,4-5,8-9,17H2,1-3H3,(H,18,21);1-2H2,(H,5,6)(H,7,8)
Dazopride is an antagonist of the 5-HT3 receptor and agonist of the 5-HT4 receptor, structurally related to metoclopramide. Dazopride was developed by A. H. Robins Company as an antiemetic and gastroprokinetic drug. Dazoptide demonstrated an antiemetic effect in the clinic after i.v. infusion to patients, receiving anticancer therapy.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6917727
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
100981-14-4
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
106613-26-7
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY | |||
|
25S5HB67BK
Created by
admin on Mon Mar 31 17:50:21 GMT 2025 , Edited by admin on Mon Mar 31 17:50:21 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
